I

I-Mab Biopharma

162 employees

I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Antibody
Product Research
Biologics
Monoclonal antibodies
Pharmaceutical
Drug Development
Immuno-oncology
Biopharmaceutical
Cancer
Bispecific antibodies

Date founded

2016

Funding rounds raised

Total raised

$418M

from 17 investors over 17 rounds

I

I-Mab Biopharma raised $418M on September 4, 2020

Investors: Lake Bleu Capital (Hong Kong) Limited, GIC, Hillhouse Capital Management, Avidity Partners, Octagon Capital, OrbiMed Advisors, Perceptive Advisors and The Invus Group

I

I-Mab Biopharma raised $27M on July 25, 2019

Investors: VMS Group

I

I-Mab Biopharma raised $220M on June 29, 2018

Investors: Tally Capital, Hillhouse Capital Management, EDBI Pte Ltd, Tasly Pharmaceutical Group Co., LTD., CDH Investments and Hony Capital

I

I-Mab Biopharma raised $150M on March 23, 2017

Investors: Genexine, Inc. and Tasly Pharmaceutical Group Co., LTD.

FAQ